Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 1.00 |
| ▸ | HSD11B2 | P80365 | 11/20 | 1.00 |
| ▸ | CES2 | O00748 | 4/20 | 1.00 |
| ▸ | CES1 | P23141 | 4/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 1/20 | 1.00 |
| ▸ | HSD17B2 | P37059 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.80 |
| ▸ | CNR1 | P21554 | 1/20 | 0.80 |
| ▸ | HTR2A | P28223 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | HTR2B | P41595 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetoxolone SCHEMBL420036 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| Acetoxolone SCHEMBL420037 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| Acetoxolone SCHEMBL11785821 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| Acetoxolone SCHEMBL15379584 | 0.99 | HSD11B1 (0.98) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL9342334 | 0.92 | HSD11B1 (0.85) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL22571029 | 0.92 | HSD11B1 (0.85) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL9652506 | 0.92 | HSD11B1 (0.85) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL9526004 | 0.92 | CES2 (1.00) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL9342337 | 0.92 | HSD11B1 (0.85) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL16003486 | 0.92 | HSD11B1 (0.85) | HSD11B1HSD11B2CES2CES1HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025060847-A1 | CYTOCHROME P450 ENZYME, NUCLEIC ACID MOLECULE, AND GLYCYRRHETINIC ACID DERIVATIVE AND USE THEREOF | 中国药科大学 | 2025-03-27 | — | — | WO | claimed |
| US-20250057962-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2025-02-20 | — | — | US | claimed |
| EP-4426712-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | Ripple Therapeutics Corporation (CA) | 2024-09-11 | — | — | EP | claimed |
| WO-2023079362-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-05-11 | — | — | WO | claimed |
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2020-02-13 | — | — | US | claimed |
| US-20180125986-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2018-05-10 | — | — | US | claimed |
| US-9622969-B2 | Polymer conjugated protein micelles | SOUTH DAKOTA STATE UNIV (US) | 2017-04-18 | — | — | US | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | SOUTH DAKOTA STATE UNIVERSITY (US) | 2014-12-18 | — | — | US | claimed |
| WO-2004006902-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006901-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| US-20040010035-A1 | Gastrointestinal compositions | MCNEIL-PPC, INC | 2004-01-15 | — | — | US | claimed |
| US-20040010034-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | claimed |
| US-20040009234-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030003140-A1 | Absorbable solid compositions for topical treatment of oral mucosal disorders | EFRAT BIOPOLYMERS LTD. | 2003-01-02 | — | — | US | claimed |
| EP-1236466-A1 | Absorbable solid compositions for topical treatment of oral mucosal disorders | Efrat Biopolymers Ltd. (IL) | 2002-09-04 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057962-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | CCND2, CCND1, C9 | HSD11B1 756/4885HSD11B2 386/4885CES2 4369/4885 |
| US-20040010034-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | HSD11B1 1084/4885HSD11B2 872/4885CES2 3921/4885 |
| US-20040009234-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | HSD11B1 1084/4885HSD11B2 872/4885CES2 3921/4885 |
| US-20040010035-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | HSD11B1 1084/4885HSD11B2 872/4885CES2 3921/4885 |
| US-20180125986-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, NOS3 | HSD11B1 1388/4885HSD11B2 1693/4885CES2 153/4885 |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | GSTK1, GSTO1, GSTM2 | HSD11B1 678/4885HSD11B2 1114/4885CES2 356/4885 |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | MTDH, PSMG3, GHITM | HSD11B1 4549/4885HSD11B2 4723/4885CES2 3378/4885 |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | HSD11B1 1531/4885HSD11B2 1788/4885CES2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.